Skip to content
Advertisement

In this Monday, Nov. 23, 2015, photo, flags fly in front of Pfizer World Headquarters, in New York. Drugmaker Pfizer said that in November 2016 it will launch a less-expensive version of rival Johnson & Johnson’s blockbuster immune disorder drug, Remicade. Pfizer’s version, called Inflectra, will hit pharmacies in late November. It will be only the second so-called biosimilar drug available in the U.S. (AP Photo/Mark Lennihan)

In this Monday, Nov. 23, 2015, photo, flags fly in front of Pfizer World Headquarters, in New York. Drugmaker Pfizer said that in November 2016 it will launch a less-expensive version of rival Johnson & Johnson’s blockbuster immune disorder drug, Remicade. Pfizer’s version, called Inflectra, will hit pharmacies in late November. It will be only the second so-called biosimilar drug available in the U.S. (AP Photo/Mark Lennihan)

Featured Photo Galleries